Reata Pharmaceuticals, Inc. - (RETA) News
Filter RETA News Items
RETA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RETA News Highlights
- RETA's 30 day story count now stands at 9.
- Over the past 25 days, the trend for RETA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about RETA are BIO, DRUG and LOAN.
Latest RETA News From Around the Web
Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.
Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio?TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […] |
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). |
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near FutureReata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would... |
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia. |
Insider Sell: SVP, Chief Accounting Officer Bhaskar Anand Sells 406 Shares of Reata ...On September 5, 2023, Bhaskar Anand, the SVP, Chief Accounting Officer of Reata Pharmaceuticals Inc (NASDAQ:RETA), sold 406 shares of the company. |
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue GrowthPharma stocks can be a great investment, particularly if they have solid performance, revenue growth and a positive outlook. |
The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failureBiogen is acquiring Reata Pharmaceuticals with the help of a hefty loan, Novo Nordisk teams up with the Broad Institute and other life sciences news you may have missed. |
Top Growth Stocks for September 2023Top growth stocks for September include Cabaletta Bio Inc., Reata Pharmaceuticals Inc., and MoonLake Immunotherapeutics. |
Top Stocks for September 2023Cabaletta Bio, Reata Pharmaceuticals, and MoonLake Immunotherapeutics provided the best 1-year total returns as of mid-August. |
The 7 Most Promising Momentum Stocks to Own NowThese momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. |